Rossari's margin slips to 11.6%, but management says that's the floor.

Tipsheet Editorial — Mon, 20 Jul 2026 18:16:44 GMT

Q1 revenue rose 28% to ₹697 cr, but EBITDA margin fell 90 bps to 11.6%. The company now sees that as a near-term base and expects B2C exit to add 2-3 ppt.

What’s new

EBITDA margin dropped 90 bps to 11.6% from 12.5% a year ago.
Management revises margin floor guidance from 12-13% to current level.
Ethylene oxide supply constrained; volume growth driven by non-EO products until December.

Why it matters

The margin slip confirms near-term pressure from institutional and consumer segments and rising costs. Yet the planned B2C exit and Thailand investment suggest management is addressing structural issues.

What we’re watching

Whether B2C exit delivers the promised 2-3 ppt margin release in coming quarters.
Impact of EO supply normalisation expected by December on product mix.
Pharma revenue guidance variability: from ₹30-50 crore to ₹70-75 crore adds uncertainty to FY27 revenue mix.

The full read

Revenue jumped 28% to ₹697 crore. Margins did not. EBITDA margin slipped 90 bps to 11.6%, weighed by institutional and consumer segments and higher freight and insurance costs — management now sees that as a near-term base, revising earlier guidance of a 12-13% floor. Ethylene oxide supply is constrained, so volume growth is coming from non-EO products until fresh material arrives before December. The B2C exit should free up 2-3 ppt of margin, and investments in Thailand and R&D target longer-term recovery, but pharma revenue guidance varied widely from ₹30-50 crore to ₹70-75 crore during the call. FY27 revenue growth guidance stays at 15%. The margin floor has moved lower, but the portfolio reset is in motion.

Primary source: BSE · NSE

Rossari Q1 revenue up 28% to ₹6,972M; profit rises but dips sequentially

Tipsheet Editorial — Sat, 18 Jul 2026 16:35:21 GMT

Revenue rose 28% YoY, net profit edged up to ₹351M from ₹336M. Sequential profit fell 24% due to seasonal fluctuations. Board approved trivial ESOP and subsidiary transfer.

What’s new

Revenue up 28% YoY to ₹6,972M; net profit ₹351M vs ₹336M a year ago.
Sequential profit fell from ₹460M in March quarter due to seasonal factors.
Board approved 4,000 ESOP grant and transfer of subsidiary to Rossari Singapore for ₹24Cr.

Why it matters

Q1 results are solid but routine: year-on-year growth is strong, but the sequential profit dip is normal seasonality. The board items are immaterial. No surprise in the print; estimates are unlikely to shift.

What we’re watching

Sustained revenue growth the rest of FY27.
Margin trajectory as volumes normalise.
Any new client wins or product expansions.

The full read

Rossari Biotech’s June-quarter revenue hit ₹6,972M, up 28% year on year. Net profit rose to ₹351M from ₹336M a year ago. Against the March quarter, however, revenue inched up just 2% while profit dropped 24% — management blamed normal seasonality. The board also approved two trivial items: an ESOP grant of 4,000 options and an internal subsidiary transfer worth ₹24 crore that has no cash-flow or valuation impact. The print is solid but unexciting; analyst notes call it routine. For a stock at 19.9x trailing earnings with 11.5% ROE, the next catalyst is likely outside this quarter's numbers.

Primary source: BSE · NSE

Rossari Biotech Ltd. (ROSSARI) — Tipsheet

Rossari's margin slips to 11.6%, but management says that's the floor.

What’s new

Why it matters

What we’re watching

The full read

Rossari Q1 revenue up 28% to ₹6,972M; profit rises but dips sequentially

What’s new

Why it matters

What we’re watching

The full read